Sondo, Paul
Tahita, Marc Christian
Rouamba, Toussaint
Derra, Karim
Kaboré, Bérenger
Compaoré, Cheick Saïd
Ouédraogo, Florence
Rouamba, Eli
Ilboudo, Hamidou
Bambara, Estelle Aïssa
Nana, Macaire
Sawadogo, Edmond Yabré
Sorgho, Hermann
Somé, Athanase Mwinessobaonfou
Valéa, Innocent
Dahal, Prabin
Traoré/Coulibaly, Maminata
Tinto, Halidou
Funding for this research was provided by:
European & Developing Countries Clinical Trials Partnership (TMA2018CDF-2365)
Article History
Received: 24 September 2020
Accepted: 8 May 2021
First Online: 24 May 2021
Declarations
:
: Prior to starting the study, the protocol was registered in ExternalRef removed (NCT04238845). The study will be conducted in compliance with fundamental ethical principles and relevant national, EU, and international regulations. The study protocol was submitted to the Ethics Committees for Health Research of the Ministry of Health of Burkina Faso and an approval from this ethical committee was obtained under the following reference number: No. 2020-01-007. Furthermore, the study protocol is reviewed and approved (deliberation No. 2020-00639) by technical committee for the examination of authorization for clinical trial requests of the national agency for pharmaceutical regulation which is the regulatory authority with the ability to authorize the conduct of any clinical trial in Burkina Faso. A written informed consent will be obtained from all the study participants before enrolment. As the study involves minors (children aged 6–59 months), the parents or guardians will be asked to sign the consent to participate in the study.
: Not applicable as no data requiring consent for publication are included in this study.
: The authors declare that they have no competing interests.